You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,828,440


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,828,440
Title:Corticosteroids for the treatment of joint pain
Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
Inventor(s): Bodick; Neil (Boston, MA), Blanks; Robert C. (Auburndale, MA), Kumar; Anjali (Belmont, MA), Clayman; Michael D. (Gloucester, MA), Moran; Mark (Orinda, CA)
Assignee: Flexion Therapeutics, Inc. (Burlington, MA)
Application Number:13/422,994
Patent Claims: 1. An injectable formulation comprising (a) controlled- or sustained-release microparticles comprising triamcinolone acetonide (TCA) or a pharmaceutically-acceptable salt thereof and a poly(lactic-co-glycolic) acid copolymer (PLGA) matrix, wherein the TCA comprises between 22% to 28% of the microparticles and wherein the PLGA has the following characteristics: (i) a molecular weight in the range of about 40 to 70 kDa; and (ii) a lactic acid:glycolic acid molar ratio of 80:20 to 60:40, and wherein the TCA is released for between at least 14 days and 90 days upon administration to a joint.

2. The formulation of claim 1, wherein the PLGA copolymer has a molar ratio of lactic acid:glycolic acid of 75:25.

3. The formulation of claim 1, wherein the microparticles further comprise a polyethylene glycol (PEG) moiety, wherein the PEG moiety comprises between 25% to 0% weight percent of the microparticle.

4. The formulation of claim 1, wherein the 22% to 28% of TCA in the microparticles comprises a total TCA load dose between 10 to 50 mg.

5. The formulation of claim 1, wherein the lactic acid-glycolic acid copolymer has an inherent viscosity in the range of 0.3 to 0.5 dL/g.

6. An injectable formulation comprising (a) controlled- or sustained-release microparticles comprising triamcinolone acetonide (TCA) or a pharmaceutically-acceptable salt thereof and a poly(lactic-co-glycolic) acid copolymer (PLGA) matrix, wherein the TCA comprises between 22% to 28% of the microparticles, wherein the microparticles have a mean diameter of between 10 .mu.m to 100 .mu.m, and wherein the PLGA has the following characteristics: (i) a molecular weight in the range of about 40 to 70 kDa; and (ii) a lactic acid:glycolic acid molar ratio of 80:20 to 60:40, wherein the TCA is released for between at least 14 days and 90 days upon administration to a joint.

7. The formulation of claim 6, wherein the PLGA copolymer has a molar ratio of lactic acid:glycolic acid of 75:25.

8. The formulation of claim 6, wherein the microparticles further comprise a polyethylene glycol (PEG) moiety, wherein the PEG moiety comprises between 25% to 0% weight percent of the microparticle.

9. The formulation of claim 6, wherein the 22 to 28% of TCA in the microparticles comprises a total TCA load dose between 10 to 50 mg.

10. The formulation of claim 6, wherein the lactic acid-glycolic acid copolymer has an inherent viscosity in the range of 0.3 to 0.5 dL/g.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.